Loading...Loading...GE Healthcare Technologies Inc GEHC reported fourth-quarter 2023 sales of $5.21 billion, up 5% Y/Y on an organic basis, slightly beating the consensus of $5.09 billion, driven by volume and price.Net income attributable to GE HealthCare was $403 million versus $554 million for the prior year, and Adjusted EBIT was $837 million versus $844 million.The company’s total book-to-bill was strong at 1.05 times.

正在加载。。。正在加载。。。GE Healthcare Technologies Inc GEHC报告称，2023年第四季度销售额为52.1亿美元，同比有机增长5%，略高于普遍预期的50.9亿美元，受销量和价格驱动。归属于GE HealthCare的净收入为4.03亿美元，上年为5.54亿美元，调整后的息税前利润为8.37亿美元，上年为8.44亿美元。该公司的账面总收入是比尔的1.05倍。

Total company orders increased 3% organically year-over-year.Also Read: General Electric Gears Up For Vernova Spin-Off Amid GEHC Stock Surge.The company posted an adjusted EPS of $1.18, compared to $1.31 in the prior year, beating the consensus of $1.07.Imaging segment revenues of $2.8 billion increased 4% Y/Y on both a reported and Organic basis.

公司总订单同比有机增长3%。另请阅读：通用电气在GEHC股价飙升之际为Vernova分拆做好准备。该公司公布的调整后每股收益为1.18美元，而去年为1.31美元，超出了普遍预期的1.07美元。成像部门收入为28亿美元，无论是报告还是有机收入，同比增长4%。

Ultrasound segment revenues of $944 million declined by 1% reported and 2% on an Organic basis.Patient Care Solutions’ Revenues of $827 million increased by 5% reported and 4% on an Organic basis. Pharmaceutical Diagnostics’ revenues of $591 million increased by 25% reported and 23% on an Organic basis.“We bolstered our market position with strategic acquisitions while at the same time paying down $1 billion in debt, setting a solid foundation for continued growth.

据报道，超声波部门的收入为9.44亿美元，下降了1%，有机收入下降了2%。据报道，患者护理解决方案的收入为8.27亿美元，增长了5%，有机增长了4%。据报道，Pharmaceutical Diagnostics的收入为5.91亿美元，增长了25%，有机收入增长了23%。“我们通过战略性收购巩固了市场地位，同时还偿还了10亿美元的债务，为持续增长奠定了坚实的基础。

We’re confident heading into 2024 amid the backdrop of an improved capital equipment landscape,” commented President and CEO Peter Arduini.Guidance: GE Healthcare forecasts for the fiscal year 2024 adjusted EPS of $4.20-$4.35, up 7%-11% Y/Y growth versus consensus of $4.24.The company forecasts annual 2024 organic revenue growth of approximately 4% year-over-year.GE Healthcare sees a fiscal year 2024 adjusted EBIT margin of 15.6%-15.9%, reflecting an expansion of 50 to 80 basis points versus the 2023 Standalone Adjusted EBIT margin of 15.1%.Price.

在资本设备状况改善的背景下，我们有信心进入2024年，”总裁兼首席执行官彼得·阿杜尼（PeterArduini）评论道。指引：GE Healthcare预测2024财年调整后的每股收益为4.20-4.35美元，同比增长7%-11%，而普遍预期为4.24美元。该公司预测2024年的年度有机收入同比增长约4%。GE Healthcare预计2024财年调整后息税前利润率为15.6%-15.9%，与2023年单独调整后息税前利润率15.1%相比，增长了50-80个基点。